134 related articles for article (PubMed ID: 35272875)
21. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.
Rungruang BJ; Miller A; Krivak TC; Horowitz NS; Rodriguez N; Hamilton CA; Backes FJ; Carson LF; Friedlander M; Mutch DG; Goodheart MJ; Tewari KS; Wenham RM; Bookman MA; Maxwell GL; Richard SD
Cancer; 2017 May; 123(6):985-993. PubMed ID: 27864921
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of supradiaphragmatic lymph nodes at initial presentation in patients with stage III high-grade serous ovarian cancer.
McIntosh LJ; O'Neill AC; Bhanusupriya S; Matalon SA; Van den Abbeele AD; Ramaiya NH; Shinagare AB
Abdom Radiol (NY); 2017 Oct; 42(10):2513-2520. PubMed ID: 28429056
[TBL] [Abstract][Full Text] [Related]
23. Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer.
Prader S; Vollmar N; du Bois A; Heitz F; Schneider S; Ataseven B; Bommert M; Waltering KU; Heikaus S; Koch JA; Alesina PF; Traut A; Harter P
Gynecol Oncol; 2019 Jan; 152(1):76-81. PubMed ID: 30463683
[TBL] [Abstract][Full Text] [Related]
24. Nodal status--its impact on prognosis in advanced ovarian cancer.
Bachmann C; Bachmann S; Fehm T; Staebler A; Becker S; Rothmund R; Gardanis C; Grischke EM; Wallwiener D; Solomayer EF
J Cancer Res Clin Oncol; 2012 Feb; 138(2):261-7. PubMed ID: 22105899
[TBL] [Abstract][Full Text] [Related]
25. Survival benefits of retroperitoneal lymphadenectomy for optimally-resected advanced ovarian high-grade serous carcinoma: a multi-institutional retrospective study.
Ikeda Y; Yoshihara M; Tamauchi S; Yokoi A; Yoshikawa N; Kajiyama H
J Gynecol Oncol; 2022 Jul; 33(4):e40. PubMed ID: 35320889
[TBL] [Abstract][Full Text] [Related]
26. Risk factors and therapeutic significance of inguinal lymph node metastasis in advanced lower rectal cancer.
Shiratori H; Nozawa H; Kawai K; Hata K; Tanaka T; Kaneko M; Emoto S; Sonoda H; Ishihara S
Int J Colorectal Dis; 2020 Apr; 35(4):655-664. PubMed ID: 32009191
[TBL] [Abstract][Full Text] [Related]
27. Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis.
Paik ES; Shim M; Choi HJ; Lee YY; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
Gynecol Oncol; 2016 Nov; 143(2):252-257. PubMed ID: 27567053
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.
Eoh KJ; Yoon JW; Lee I; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
J Surg Oncol; 2017 Sep; 116(3):329-336. PubMed ID: 28542980
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer.
Ataseven B; Grimm C; Harter P; Prader S; Traut A; Heitz F; du Bois A
Gynecol Oncol; 2014 Dec; 135(3):435-40. PubMed ID: 25312398
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
[No Abstract] [Full Text] [Related]
32. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
33. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
[TBL] [Abstract][Full Text] [Related]
34. Impact of Laparoscopy to Assess Resectability in Stage IIIC Epithelial Ovarian, Tubal and Peritoneal Cancer Patients.
Sánchez-Iglesias JL; Perez-Benavente A; Correa-Paris A; De la Torre Fernandez de Vega J; Carbonell Socias M; Gil-Moreno A
Gynecol Obstet Invest; 2019; 84(3):259-267. PubMed ID: 30428466
[TBL] [Abstract][Full Text] [Related]
35. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study.
Rungruang B; Miller A; Richard SD; Hamilton CA; Rodriguez N; Bookman MA; Maxwell GL; Krivak TC; Horowitz NS
Gynecol Oncol; 2012 Jan; 124(1):53-8. PubMed ID: 22032836
[TBL] [Abstract][Full Text] [Related]
36. [Clinical Study of Inguinal Lymph Node Metastasis in Anal Canal Adenocarcinoma].
Sato H; Masumori K; Koide Y; Hiro J; Tajima Y; Kamiya T; Cheong Y; Toyama K; Suda K
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1944-1946. PubMed ID: 35045455
[TBL] [Abstract][Full Text] [Related]
37. Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer.
Aletti GD; Dowdy S; Podratz KC; Cliby WA
Am J Obstet Gynecol; 2006 Dec; 195(6):1862-8. PubMed ID: 17132488
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients.
Iwase H; Takada T; Iitsuka C; Nomura H; Abe A; Taniguchi T; Takizawa K
J Gynecol Oncol; 2015 Oct; 26(4):303-10. PubMed ID: 26197771
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.
Suidan RS; Leitao MM; Zivanovic O; Gardner GJ; Long Roche KC; Sonoda Y; Levine DA; Jewell EL; Brown CL; Abu-Rustum NR; Charlson ME; Chi DS
Gynecol Oncol; 2015 Aug; 138(2):246-51. PubMed ID: 26037900
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.
Landrum LM; Java J; Mathews CA; Lanneau GS; Copeland LJ; Armstrong DK; Walker JL
Gynecol Oncol; 2013 Jul; 130(1):12-8. PubMed ID: 23578540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
